This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Uveitis  • Prognosis/ Outcomes  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Debra A. Goldstein, MD, FRCSC; David G. Godfrey, MD; Anthony Hall, MD; David G. Callanan, MD; Glenn J. Jaffe, MD; P. Andrew Pearson, MD; Dale W. Usner, PhD; Timothy L. Comstock, OD

Arch Ophthalmol. 2007;125(11):1478-1485. Published online October 8, 2007 (doi:10.1001/archophthalmol.125.11.ecs70063).

Objective  To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.

Design  Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.

Results  During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively. Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes. Intraocular pressure–lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year. The rate of hypotony (IOP  5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).

Conclusion  Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.

Author Affiliations: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago (Dr Goldstein); Glaucoma Associates of Texas (Dr Godfrey) and University of Texas Southwestern Medical School (Drs Godfrey and Callanan), Dallas, and Texas Retina Associates, Arlington (Dr Callanan); The Royal Melbourne Hospital, Victoria, Australia (Dr Hall); Duke University Eye Center, Durham, North Carolina (Dr Jaffe); Department of Ophthalmology and Visual Science, University of Kentucky, Lexington (Dr Pearson); and Bausch & Lomb, Rochester, NY (Drs Usner and Comstock).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Uveitis Treated With Fluocinolone Acetonide Implants
Francesco Viola, Giovanni Staurenghi, and Roberto Ratiglia
Arch Ophthalmol. 2009;127(1):115-116.
EXTRACT | FULL TEXT  

Uveitis Treated With Fluocinolone Acetonide Implants—Reply
Debra A. Goldstein, David G. Godfrey, Anthony Hall, David G. Callanan, Glenn J. Jaffe, P. Andrew Pearson, Dale W. Usner, and Timothy L. Comstock
Arch Ophthalmol. 2009;127(1):116.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Uveitis Treated With Fluocinolone Acetonide Implants--Reply
Goldstein et al.
Arch Ophthalmol 2009;127:116-116.
FULL TEXT  

Uveitis Treated With Fluocinolone Acetonide Implants
Viola et al.
Arch Ophthalmol 2009;127:115-116.
FULL TEXT  

Treatment of Posterior Uveitis With a Fluocinolone Acetonide Implant: Three-Year Clinical Trial Results
Callanan et al.
Arch Ophthalmol 2008;126:1191-1201.
ABSTRACT | FULL TEXT  

Fluocinolone Acetonide for the Treatment of Uveitis: Weighing the Balance Between Local and Systemic Immunosuppression
Yeh and Nussenblatt
Arch Ophthalmol 2008;126:1287-1289.
FULL TEXT